Potentially Life-Changing Beovu Side Effects, Root Cause Remains Uncertain, Medical Management Methods Being Developed
(Posted by Tom Lamb at DrugInjuryWatch.com)
From a December 1, 2020 Ocular Surgery News article, "Retina specialists receptive but cautious regarding use of Beovu", we get this snapshot view of the still-developing safety issue of significant vision loss following Beovu injections:
“[Beovu (brolucizumab)] is, at this stage, a risk-benefit question,” Nancy M. Holekamp, MD, said....
“The question is whether it is worth taking the very small risk of intraocular inflammation [following a Beovu injection] that could potentially cause irreversible vision loss when we have three well-established, effective agents that don’t carry this potential risk,” Holekamp said....
According to Holekamp, the 4.6% rate of inflammatory reactions seen in the trials, which was higher than the rate seen in contemporary trials for currently available Lucentis (ranibizumab, Genentech) and aflibercept, was likely a safety signal that may have been overlooked by the FDA approval process [for Beovu].
“And it turned out to be a significant one, as after [Beovu] was launched, we started seeing cases of severe, irreversible vision loss,” she said.
__________________________________________________________________
Beovu
Free Case Evaluation
Strictly Confidential, No Obligation.
__________________________________________________________________
Here are two recent medical journal articles that address (1) the ongoing investigation to find the root cause of these Beovu vision loss cases, and (2) the search for the best medical management or treatment methods for Beovu patients with occlusive retinal vasculitis resulting in vision loss:
- "Risk of inflammation, retinal vasculitis and retinal occlusion-related events with brolucizumab: post-hoc review of HAWK and HARRIER", published November 15, 2020, by the medical journal Ophthalmology.
- "Expert Opinion on Management of Intraocular Inflammation, Retinal Vasculitis, and/or Vascular Occlusion after Brolucizumab Treatment", published September 28, 2020, by the medical journal Ophthalmology Retina.
Starting back in February 2020, we have been investigating possible Beovu lawsuits for patients who have suffered vision loss or blindness due to Beovu-related retinal vasculitis or other Beovu side effects. If we can be of assistance to you or someone else regarding a Beovu vision loss case, you can send an email to Tom Lamb or you can call us on our toll-free number: 800-426-9535.
DrugInjuryLaw.com: Medical & Legal Information About Drug Side Effects (All website content by attorney Tom Lamb)
Drug Injury Case Evaluation - Free. Confidential. No Obligation. (Case review is done by attorney Tom Lamb)